Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,040 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of the Breast Clear all

Conditions: Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions: vorinostat, conventional surgery; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: KIBUR MICRODEVICE, anthracycline and taxane based chemotherapy; Device · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions: galinpepimut-S, pembrolizumab, Montanide, GM-CSF; Biological · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Santa Rosa, California • Whittier, California • Miami, Florida + 9 more

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer
Interventions: Gemcitabine, Bevacizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Fresno, California • San Diego, California + 13 more

Conditions: Breast Cancer Female
Interventions: OCT- based investigational imaging device; Device
Lead sponsor: Perimeter Medical Imaging; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cottonwood, Arizona

Conditions: Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: NZV930, PDR001, NIR178; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Tampa, Florida • Houston, Texas

Conditions: Malignant Tumor
Interventions: Novilase Interstitial Laser Therapy; Device
Lead sponsor: Novian Health Inc.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 9
States / cities: Tucson, Arizona • Denver, Colorado • Bartlett, Illinois + 6 more

Conditions: Breast Cancer
Interventions: gemcitabine/carboplatin, iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 18
States / cities: Birmingham, Alabama • Denver, Colorado • Torrington, Connecticut + 15 more

Conditions: Breast Cancer
Interventions: capecitabine, irinotecan hydrochloride; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Interventions: ADRX-0706; Drug
Lead sponsor: Adcentrx Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Los Angeles, California • St. Petersburg, Florida • Tampa, Florida + 8 more

Conditions: Advanced Solid Tumors, Advanced Breast Cancer
Interventions: ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant; Drug
Lead sponsor: Ensem Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Breast Cancer, Infertility
Interventions: Letrozole; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Years to 45 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
Interventions: Nab-Paclitaxel, Paclitaxel, Docetaxel, Phesgo, T-DM1, Pertuzumab, Trastuzumab Deruxtecan, Trastuzumab Subcutaneous Subcutaneous, Tucatinib, Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: High Risk for Invasive Breast Cancer
Interventions: Tamoxifen, Tamoxifen (Nolvadex); Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 30 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Menopause
Interventions: Personalized risk assessment, genetic counseling intervention; Procedure
Lead sponsor: Yale University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer
Interventions: gemcitabine/carboplatin, Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 102
States / cities: Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions: TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more

Conditions: Breast Cancer
Interventions: CyberKnife Partial Breast Irradiation; Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 45 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer Related Lymphedema, Covid19
Interventions: Survey; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: DCIS
Interventions: MammoSite Radiation Therapy System; Device
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • Inglewood, California • Los Angeles, California + 9 more

Conditions: Breast Neoplasms
Interventions: Abemaciclib, Standard Adjuvant ET, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Glendale, Arizona • Los Angeles, California • Hollywood, Florida + 7 more

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Lymphoma Cancer, Gynecological Cancers
Interventions: group intervention and questionnaires, individual phone intervention and questionnaires, expressive writing (arm will not be include in the randomization); Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 70 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: questionnaire administration, digital mammography, positron emission mammography; Other · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 35 Years and older · Female only
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

Intraoperative Use of an Optical Coherence Tomography (OCT) Imaging System to Guide Additional Margin Cavity Shaves in Breast Conserving Surgery (BCS)

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

A Multicenter "Ablate and Resect" Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer

A Study of ADRX-0706 in Select Advanced Solid Tumors

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

SHORTened Duration of TAMoxifen

Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Breast Cup Immobilization Device II (GCC 1047)

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

A Pilot Study of CyberKnife Radiosurgery Delivered to the Partial Breast

Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment

MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer

Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer